(2R,3R,4R,5R)-5-(6-aminopurin-9-yl)-4-fluoro-2-(hydroxymethyl)oxolan-3-ol

We are (2R,3R,4R,5R)-5-(6-aminopurin-9-yl)-4-fluoro-2-(hydroxymethyl)oxolan-3-ol CAS:64183-27-3 manufacturer and supplier in China, Pls send inquiry of to info@nbinno.com of visit www.nbinno.com our official website should you have any interests

Chemical Name:(2R,3R,4R,5R)-5-(6-aminopurin-9-yl)-4-fluoro-2-(hydroxymethyl)oxolan-3-ol
CAS.NO:64183-27-3
Synonyms:2'F-dA
2'-Deoxy-2'-fluoroadenosine
2'-fluoro-2'-deoxy-adenosine
Adenosine,2'-deoxy-2'-fluoro
Molecular Formula:64183-27-3
Molecular Weight:269.23200
 
Physical and Chemical Properties:
Density:2.01
Boiling point:628.6ººC
Flash point:334ºC
Index of Refraction:1.834
 
Specification:
Appearance:White to off-white powder
Assay(HPLC):≥98.0%
Assay(UV):≥98.0%
Moisture:≤11.0%
 
Packing:25 kg/drum, can also be packaged according to customer requirements
Storage:Store in a cool, ventilated place
Application:Intermediate of pharmaceutical 

(2R,3R,4R,5R)-5-(6-aminopurin-9-yl)-4-fluoro-2-(hydroxymethyl)oxolan-3-ol


Related News: With the speeding up of review and approval, the number of approved innovative drugs in China is about to usher in a year of blowout.Cyclopropylboronic acid With the speeding up of review and approval, the number of approved innovative drugs in China is about to usher in a year of blowout.2-(Heptafluoropropoxy)hexafluoropropyl Trifluorovinyl Ether “This is particularly important in reducing overall disease burden. Moreover, this strategic decision will not only strengthen our diabetes portfolio but also help consolidate our position as the fastest-growing player in the anti-diabetes segment,” Mankind Pharma Director of Marketing Sanjay Koul said in a statement.o-cresol CAS:95-48-7 “This is particularly important in reducing overall disease burden. Moreover, this strategic decision will not only strengthen our diabetes portfolio but also help consolidate our position as the fastest-growing player in the anti-diabetes segment,” Mankind Pharma Director of Marketing Sanjay Koul said in a statement.”This is particularly important in reducing overall disease burden. Moreover, this strategic decision will not only strengthen our diabetes portfolio but also help consolidate our position as the fastest-growing player in the anti-diabetes segment,” Mankind Pharma Director of Marketing Sanjay Koul said in a statement.

Related Products
Product Name
Lithium Trifluoromethanesulfonate View Details
(R)-(+)-1-Boc-3-aminopyrrolidine View Details
2,7-Dihydroxynaphthalene View Details
1,1-Cyclohexanediacetic acid mono amide manufacturer Docosahexaenoic Acid manufacturer ethyl oleate manufacturer tert-butyl (S)-2-((aminooxy)methyl)pyrrolidine-1-carboxylate manufacturer 3-(Difluoromethoxy)aniline manufacturer